2D NMR Spectroscopy for Therapeutic Peptide Structural Characterization: COSY, TOCSY, and NOESY
Introduction: Why 2D NMR for Peptide Characterization Is an Essential Tool in Therapeutic Development When a therapeutic peptide progresses into […]
PLGA Nanoparticles vs Microspheres: Which Platform Is Right for Your Drug Delivery Application?
Introduction: When developing a next-generation injectable, implantable, or targeted therapy using poly(lactic-co-glycolic acid) (PLGA), one of the most consequential early
Case Study: Dual Analyte LC-MS/MS Bioanalysis for an Antibody-Drug Conjugate Program
Introduction: The Bioanalytical Complexity of ADC Programs Bioanalysis for an Antibody-Drug Conjugate Program is far from a straightforward analytical exercise.
Case Study: Dual Analyte LC-MS/MS Bioanalysis for an Antibody-Drug Conjugate Program Read More »
Nitrosamine Testing for Inhalation Drug Products: MDIs, DPIs, and Nasal Sprays
Introduction: Nitrosamine Testing Inhalation Drug Products MDI DPI Nasal Spray has become a critical focus area for pharmaceutical manufacturers after
Nitrosamine Testing for Inhalation Drug Products: MDIs, DPIs, and Nasal Sprays Read More »
How to Build a Scientifically Justified AET for Extractables and Leachables (E&L) Studies
Introduction: Why AET Derivation Is the Defining Step in E&L Studies The Analytical Evaluation Threshold (AET) is the single most
Peptide Biosimilar Characterization Using LC-MS: Challenges and Analytical Solutions
Introduction: Why Peptide Biosimilar Characterization Using LC-MS Requires More Than Conventional Proteomics Peptide biosimilar characterization using LC-MS is far more
Peptide Biosimilar Characterization Using LC-MS: Challenges and Analytical Solutions Read More »
In Silico Potency Prediction for NDSRIs: Using SAR, DEREK, and CASE Ultra for Hazard Classification
Introduction: Why Conventional Mutagenicity Models Are Inadequate for NDSRIs The regulatory complexity associated with N-Nitrosamine Drug Substance-Related Impurities (NDSRIs) extends
Anti-Drug Antibody (ADA) Assay Development and Validation Services for Biologic Therapies
Introduction: Anti-Drug Antibody (ADA) Assay Development Services play a critical role in evaluating the immunogenicity of biologic therapies. As biologics
Regulated Bioanalytical Services for NDA and BLA Submissions: What to Look for in a CRO
Introduction: Why CRO Selection Is a Regulatory Decision, Not Just a Scientific One When sponsors prepare regulated bioanalytical services for
Regulated Bioanalytical Services for NDA and BLA Submissions: What to Look for in a CRO Read More »
How to Investigate Unknown Peaks in Extractables & Leachables Study
Introduction: The Most Overlooked Challenge in E&L Science Unknown Peak Identification in Extractables and Leachables (E&L) testing is among the
How to Investigate Unknown Peaks in Extractables & Leachables Study Read More »